Clinical Trial

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Study acronym: CARABELA
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative high/intermediate risk breast cancer patients
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-02-28; most recent amendment 2026-02-19.
Status change: Recruiting → Active, Not Recruiting 2022-07-11
Status change: Not Yet Recruiting → Recruiting 2020-09-28
Trial Details
NCT Number NCT04293393
Lead Sponsor Spanish Breast Cancer Research Group
Collaborators: Eli Lilly and Company
Conditions Early Breast Cancer
Enrollment 200 participants
Start Date 2020-10-02
Primary Completion 2023-06-21 (estimated)
Study Completion 2033-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-12